Answers are grounded in this paper and cite their sources.
The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response among patients with HER2-negative early-stage breast cancer. Efficacy was restricted primarily to patients with triple-negative tumors, in whom the pathological complete response is considered to be a reliable predictor of long-term outcome. (Funded by Sanofi-Aventis and Roche, Germany; ClinicalTrials.gov number, NCT00567554.).
No takes yet. Share an insight, caveat, or question.
Minckwitz et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: